MDSpire - Summary
Clinical Guidelines

Mapping Carbon Hotspots in Pharma Supply Chains

New framework combining LCA and network analysis reveals hidden leverage points for decarbonization in complex drug supply networks

  • March 30, 2026

  • 2 min

Share

A comprehensive study indicates that successful carbon reduction in pharmaceutical supply chains hinges more on the strategic positioning of processes within the network rather than solely on their individual emissions. Researchers employed life cycle assessment (LCA) and social network analysis (SNA) to evaluate emissions from various supply chain nodes for drugs like polymyxin B and acarbose. The introduction of a responsibility contribution index (RCI) highlights central players, such as logistics hubs, that disproportionately influence overall carbon footprints, directing attention towards effective decarbonization strategies.

Original Source(s)

Mapping Carbon Hotspots in Pharma Supply Chains

  • March 30, 2026

Related Content

GlycoRNA Comes into Focus with Mass Spectrometry Blueprint

New review maps analytical workflows to decode a surprising class of sugar-coated RNA

  • March 30, 2026

  • 2 min
Root Canal Treatment Linked to Metabolic Improvements

Longitudinal NMR metabolomics study suggests clearing apical periodontitis may reduce systemic inflammation and improve glucose and lipid profiles

  • March 30, 2026

  • 3 min
FDA Approval Advances Basal Insulin

Weekly dosing reduces injection frequency vs daily regimens, with phase 3 data supporting efficacy and class-consistent safety.